← Back to Search

Behavioral Intervention

Mindfulness-Based Neurofeedback for Borderline Personality Disorder (MIND-BPD Trial)

Phase 2

Waitlist Available

Led By Sarah K Fineberg, MD PhD

Research Sponsored by Yale University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 18-60

Be between 18 and 65 years old

Must not have

Daytime sedating medications (e.g. benzodiazepines, opiates, sedating neuroleptics)

Any scheduled daily benzodiazepines

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from baseline (immediately before neurofeedback) to immediately after neurofeedback on the same day

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to see if using real-time brain imaging with mindfulness techniques can enhance therapy for adults with Borderline Personality Disorder.

Who is the study for?

This trial is for adults with Borderline Personality Disorder (BPD) who are seeking to enhance their psychotherapy outcomes. Specific eligibility criteria details were not provided, so interested individuals should contact the study organizers for more information.

What is being tested?

The trial is examining if mindfulness-based real-time fMRI neurofeedback (mbNF) can improve the effectiveness of established psychotherapy methods for BPD compared to a control neurofeedback.

What are the potential side effects?

Potential side effects are not detailed in the provided information. However, participants may experience discomfort or anxiety related to fMRI procedures or stress from focusing on mental states during mbNF.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 60 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am not taking any sedatives like benzodiazepines or opiates during the day.

Select...

I take benzodiazepines daily.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from baseline (immediately before neurofeedback) to immediately after neurofeedback on the same day

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from baseline (immediately before neurofeedback) to immediately after neurofeedback on the same day

This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline (immediately before neurofeedback) to immediately after neurofeedback on the same day for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in DMN-Frontoparietal Control Network (FPCN) anticorrelation in resting state functional connectivity data after one session of neurofeedback

Change in within-Default Mode Network (DMN) resting state functional connectivity after one session of neurofeedback (NF)

Secondary study objectives

Change from baseline in state mindfulness on State Mindfulness Scale (SMS) score on same day after neurofeedback.

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: mindfulness-based NeurofeedbackExperimental Treatment1 Intervention

Participants will participate in one session of mindfulness-based fMRI neurofeedback followed by 20 weeks of remote online weekly Dialectical Behavior Therapy skills group.

Group II: control NeurofeedbackExperimental Treatment1 Intervention

Participants will participate in one session of control fMRI neurofeedback followed by 20 weeks of remote online weekly Dialectical Behavior Therapy skills group.

0 / 3Eligibility criteria met